BN Business News
Ajouter votre entreprise →
Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.

Entreprise · 31/03/20151 min de lecture

Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information; Guidance for Industry; Request for Comments

Traduction automatique locale · Langue originale de la source

Résumé

The Food and Drug Administration (FDA) is announcing a request for additional comments on the chemistry, manufacturing, and control (CMC) information that a sponsor of an investigational new drug application (IND) should provide in its IND in order to meet regulatory requirements when commercially available foods or dietary supplements containing live biotherapeutic products (LBPs) are used as investigational new drugs in early phase clinical trials. The request for additional comments on the CMC information is related to the guidance entitled, "Early Clinical Trials with Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information; Guidance for Industry," dated February 2012 (February 2012 guidance).

Langue originale de la source: Federal Register — Food and Drug AdministrationOuvrir le communiqué original →

Explorer les analyses

Analyses business →